QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

HOME  |   SEARCH  |   ARCHIVE  |   SUBSCRIBE  |   CONTACT  |   HELP

This Article Full Text Full Text (PDF) Submit an eLetter Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (42) Citing Articles via Google Scholar Google Scholar Articles by Binder, E. B. Articles by Nemeroff, C. B. Search for Related Content PubMed PubMed Citation Articles by Binder, E. B. Articles by Nemeroff, C. B.

 Previous Article  |  Next Article 

The Journal of Neuroscience, January 15, 2001, 21(2):601-608

Enhanced Neurotensin Neurotransmission Is Involved in the Clinically Relevant Behavioral Effects of Antipsychotic Drugs: Evidence from Animal Models of Sensorimotor Gating

Elisabeth B. Binder¹, Becky Kinkead², Michael J. Owens², Clinton D. Kilts², and Charles B. Nemeroff²

¹ Max Planck Institute for Psychiatry, 80804 Munich, Germany, and ² Laboratory of Neuropsychopharmacology, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia 30322

To date, none of the available antipsychotic drugs are curative, all have significant side-effect potential, and a receptor-binding profile predictive of superior therapeutic ability has not been determined. It has become increasingly clear that schizophrenia does not result from the dysfunction of a single neurotransmitter system, but rather from an imbalance between several interacting systems. Targeting neuropeptide neuromodulator systems that concertedly regulate all affected neurotransmitter systems could be a promising novel therapeutic approach for schizophrenia. A considerable database is concordant with the hypothesis that antipsychotic drugs act, at least in part, by increasing the synthesis and release of the neuropeptide neurotensin (NT). In this report, we demonstrate that NT neurotransmission is critically involved in the behavioral effects of antipsychotic drugs in two models of antipsychotic drug activity: disrupted prepulse inhibition of the acoustic startle response (PPI) and the latent inhibition (LI) paradigm. Blockade of NT neurotransmission using the NT receptor antagonist 2-[[5-(2,6-dimethoxyphenyl)-1-(4-(N-(3-dimethylaminopropyl)-N-methylcarbamoyl)-2-isopropylphenyl)-1H- pyrazole-3-carbonyl]-amino]-adamantane-2-carboxylic acid, hydrochloride (SR 142948A) prevented the normal acquisition of LI and haloperidol-induced enhancement of LI. In addition, SR 142948A blocked the PPI-restoring effects of haloperidol and the atypical antipsychotic drug quetiapine in isolation-reared animals deficient in PPI. We also provide evidence of deficient NT neurotransmission as well as a left-shifted antipsychotic drug dose-response curve in isolation-reared rats. These novel findings, together with previous observations, suggest that neurotensin receptor agonists may represent a novel class of antipsychotic drugs.

Key words: prepulse inhibition; latent inhibition; haloperidol; quetiapine; SR 142948A; isolation rearing

---

Copyright © 2001 Society for Neuroscience  0270-6474/01/212601-08$05.00/0

This article has been cited by other articles:

				N. Kojima, G. Borlikova, T. Sakamoto, K. Yamada, T. Ikeda, S. Itohara, H. Niki, and S. Endo Inducible cAMP Early Repressor Acts as a Negative Regulator for Kindling Epileptogenesis and Long-Term Fear Memory J. Neurosci., June 18, 2008; 28(25): 6459 - 6472. [Abstract] [Full Text] [PDF]

				S. Grimond-Billa, C Norman, G. Bennett, and H. Cassaday Selectively increased trace conditioning under the neurotensin agonist PD 149163 in an aversive procedure in which SR 142948A was without intrinsic effect J Psychopharmacol, May 1, 2008; 22(3): 290 - 299. [Abstract] [PDF]

				B. Kinkead, P. R. Dobner, V. Egnatashvili, T. Murray, N. Deitemeyer, and C. B. Nemeroff Neurotensin-Deficient Mice Have Deficits in Prepulse Inhibition: Restoration by Clozapine but Not Haloperidol, Olanzapine, or Quetiapine J. Pharmacol. Exp. Ther., October 1, 2005; 315(1): 256 - 264. [Abstract] [Full Text] [PDF]

				H. Y. Meltzer, L. Arvanitis, D. Bauer, W. Rein, and Meta-Trial Study Group Placebo-Controlled Evaluation of Four Novel Compounds for the Treatment of Schizophrenia and Schizoaffective Disorder Am J Psychiatry, June 1, 2004; 161(6): 975 - 984. [Abstract] [Full Text] [PDF]

				S. J. Crocker, P. D. Smith, V. Jackson-Lewis, W. R. Lamba, S. P. Hayley, E. Grimm, S. M. Callaghan, R. S. Slack, E. Melloni, S. Przedborski, et al. Inhibition of Calpains Prevents Neuronal and Behavioral Deficits in an MPTP Mouse Model of Parkinson's Disease J. Neurosci., May 15, 2003; 23(10): 4081 - 4091. [Abstract] [Full Text] [PDF]

				E. B. Binder, B. Kinkead, M. J. Owens, and C. B. Nemeroff Neurotensin and Dopamine Interactions Pharmacol. Rev., December 1, 2001; 53(4): 453 - 486. [Abstract] [Full Text] [PDF]

Home  |   Search  |   Archive  |   Subscribe  |   Contact  |   Help